Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Leap Therapeutics in a research report ...

Leap Therapeutics, Inc. (NASDAQ:LPTX) released significant updates regarding its recent clinical findings and corporate presentation. In a press release titled “Leap Therapeutics Reports Initial ...

The most recent announcement from Laowa is not a new lens but the release of the company’s new short film, The Leap Beneath, ...

When we came upon this area, I told my husband to stop. I took a few shots, and this was my favorite,' Wendy Hampe said.

Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

Leap Therapeutics (LPTX) stock extends losses as Baird downgrades citing disappointing trial data the company posted for its lead asset sirexatamab. Read more here.

Last week, we looked at occurrences at Lover’s Leap from 1915 through 1938; this week we will cover from the forties to the ...

Leap Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -70.45%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...

Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after after the company ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...